Abstracts tagged "Gastrointestinal complications and systemic sclerosis"

Abstract Number: 792 • 2018 ACR/ARHP Annual Meeting
Evaluation of Esophageal Dysmotility in Systemic Sclerosis: Clinical VALUE of Computed Tomography
Cristina Sobrino¹, Cristina Pijoan-Moratalla¹, Nicolás Almeida-Arostegui², Luis Gorospe-Sarasúa² and Carlos de la Puente-Bujidos¹, ¹Rheumatology Unit. Ramón y Cajal University Hospital, Madrid, Spain, ²Radiology Unit. Ramón y Cajal University Hospital, Madrid, Spain
Background/Purpose: Esophageal dysmotility is common in Systemic Sclerosis (SSc), affecting 50-80% of patients, usually associated with poor prognosis. SSc leads to atrophy and fibrosis of…
Abstract Number: 813 • 2018 ACR/ARHP Annual Meeting
Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction
Tasneam Shagroni¹, David Lin², Jeremy Wang², Isela Valera³, Aly M Aly⁴, Philip J. Clements², Daniel E. Furst², Rajan Saggar⁵, Jeffrey Conklin⁶ and Suzanne Kafaja², ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, ⁴Alexandria University Faculty of Medicine, Alexandria, Egypt, ⁵UCLA, Los Angeles, CA, ⁶Medicine, University of California Los Angeles, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) patients frequently have upper gastrointestinal (GI) symptoms, with GI involvement being the leading cause of morbidity. Meanwhile, interstitial lung disease (ILD)…
Abstract Number: 947 • 2017 ACR/ARHP Annual Meeting
Norway As a National Reference Population for Systemic Sclerosis; Preliminary Results from a Complete, Nationwide Cohort
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Anne Kristine Halse², Marit Seip³, Marianne Wallenius⁴, Helle Bitter⁵, Torhild Garen¹, Oyvind Midtvedt¹ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Haukeland University Hospital, Bergen, Norway, ³University Hospital of North Norway, Tromso, Norway, ⁴St. Olav's University Hospital, Trondheim, Norway, ⁵Hospital of Southern Norway, Kristiansand, Norway
Background/Purpose: To fully understand the impact of Systemic sclerosis (SSc) there is a need to complement existing multi-center registry data with novel, unbiased, high resolution…
Abstract Number: 2667 • 2017 ACR/ARHP Annual Meeting
The Association between Two Non-Invasive Methods for the Assessment of Severity of Gastrointestinal Involvement and Malnutrition in Systemic Sclerosis: Self-Reported Questionnaires and Nail Fold Video-Capillaroscopy
Yasemin Yalçınkaya¹, Zeynep Erturk¹, Ozlem Pehlivan², Ali Ugur Unal³, Pamir Atagunduz¹, Haner Direskeneli¹ and Nevsun Inanc¹, ¹Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Umraniye Education and Research Hospital, Istanbul, Turkey, ³Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey
Background/Purpose: Gastrointestinal (GI) system involvement is commonly seen in sytemic sclerosis (SSc) up to 90% of the patients during disease duration and one of the…
Abstract Number: 2676 • 2017 ACR/ARHP Annual Meeting
Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis
Rodrigo Aguila Maldonado¹, Pierina Sansinanea², Claudia Elizabeth Pena¹, Ana Carolina Costi¹, Ariel Vulcano², Adriana Testi², Mariana Pera³, Lucila García², Valeria Arturi³, Viviana Nagua² and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology, HIGA General San Martin La Plata, la plata, Argentina, ³HIGA General San Martin La Plata, la plata, Argentina
Background/Purpose: Esophageal involvement is common in Systemic Sclerosis (SSc). It is estimated to occur in 70-90% of patients. Esophageal motor dysfunction is characterized by hypotonia…
Abstract Number: 2684 • 2017 ACR/ARHP Annual Meeting
Regional and Whole Gut Transit Times in Patients with Systemic Sclerosis Using the Wireless Motility Capsule
Neetu Bali¹, Isela Valera², Aly Aly³, Jeffrey Conklin⁴, Daniel E. Furst⁵ and Suzanne Kafaja⁶, ¹Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Chamblion St,, Alexandria Faculty of Medicine, Alexandria, Egypt, ⁴Medicine, Division of Digestive Diseases at UCLA, Los Angeles, CA, Los Angeles, CA, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: The Gastrointestinal tract (GI) is one of the most commonly affected systems in systemic sclerosis (SSc), impacting the lives of up to 90% of…
Abstract Number: 2016 • 2016 ACR/ARHP Annual Meeting
Esophageal Disease in Systemic Sclerosis: Does Heritability Play a Role?
Latifa Fakoya¹, Kathryn Peterson², Andrew Gawron², Jathine Wong³, Mary Beth Scholand⁴, Allen D. Sawitzke⁵ and Tracy M. Frech^6,7, ¹Internal Medicine/Rheumatology, University of Utah, Salt Lake City, UT, ²Internal Medicine/Gastroenterology, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake, UT, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Univ of Utah, Salt Lake City, UT, ⁶Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ⁷Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT
Background/Purpose: Systemic sclerosis (SSc) associated gastroesophageal reflux disease (GERD) can cause symptoms of dysphagia and heartburn, and is associated with esophagitis, stricture, Barrett’s esophagus, and…
Abstract Number: 848 • 2016 ACR/ARHP Annual Meeting
Efficacy of Prucalopride in the Treatment of Systemic Sclerosis-Related Intestinal Involvement: Results from an Open Label Cross-over Study
Barbara Vigone¹, Monica Caronni¹, Adriana Severino¹, Chiara Bellocchi², Anna Rita Baldassarri³, Gaia Montanelli⁴, Alessandro Santaniello¹ and Lorenzo Beretta¹, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases,, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ³Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁴Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
Background/Purpose: The gastrointestinal tract (GIT) is frequently affected in SSc patients as a consequence of a reduction in enteric propulsive forces. Due to intestinal involvement,…
Abstract Number: 1897 • 2016 ACR/ARHP Annual Meeting
Vitamin-D Levels and Gastrointestinal (GI) Manifestations in Systemic Sclerosis (SSc)
Suzanne Kafaja¹, Aly Aly², Yossra A Suliman³, Mohamed Alemam⁴, Philip J. Clements⁵ and Daniel E. Furst⁶, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Chamblion St,, Alexandria Faculty of Medicine, Alexandria, Egypt, ³Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ⁴Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: The GI tract is one of the most commonly affected systems in SSc patients. GI disease in SSc patients is thought to be multifactorial…
Abstract Number: 1881 • 2015 ACR/ARHP Annual Meeting
Is the Presence of Esophageal Dilation a Poor Prognostic Factor in Dilated Interstitial Lung Disease Associated with Systemic Sclerosis?
Javier Narváez¹, Sergi Heredia², Helena Borrell Paños², Eulalia Armengol², Eugenia De Lama³ and Jose Antonio Narvaez³, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Radiology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Several studies have shown that gastroesophageal reflux disease (GERD) is a risk factor in the progression of idiopathic pulmonary fibrosis. In systemic sclerosis (SSc),…
Abstract Number: 2996 • 2014 ACR/ARHP Annual Meeting
Intestinal Pseudo-Obstruction in Patients with Systemic Sclerosis: An Analysis of the Nationwide Inpatient Sample
Antonia Valenzuela¹, Shufeng Li², Laren Becker³, Nielsen Fernandez-Becker³, Dinesh Khanna⁴, Linda Nguyen³ and Lorinda Chung⁵, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Dermatology, Stanford University School of Medicine, Palo Alto, CA, ³Gastroenterology & Hepatology, Stanford University School of Medicine, Palo Alto, CA, ⁴University of Michigan Health System, Ann Arbor, MI, ⁵Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Intestinal pseudo-obstruction accounted for 3.7% of hospitalizations of patients with systemic sclerosis (SSc), and led to death in 10% of patients in a previous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].